ALEXANDRIA, Va., Nov. 6 -- United States Patent no. 12,459,920, issued on Nov. 4, was assigned to Monte Rosa Therapeutics AG (Basel, Switzerland).
"Targeted protein degradation" was invented by Elisa Liardo (Basel, Switzerland), Laura Ann McAllister (Basel, Switzerland) and Bernhard Fasching (Basel, Switzerland).
According to the abstract* released by the U.S. Patent & Trademark Office: "This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and/or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome ...